Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
449
datasets available to search
ShareScore release 0.9.0
Dataset results
449 results for “Hypofractionation”
Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate
ClinicalTrials.gov study NCT01508390. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study Comparing Hypofractionated Dose Escalated VMAT to Conventional CCRT in Locally Advanced Head and Neck Cancer
ClinicalTrials.gov study NCT03699969. IPD Sharing: NO. Countries: 0. Publications: 0.
Dosimetric Comparison of Three Radiation Techniques for Hypofractionated Whole Breast Radiotherapy in Early Breast Cancer
ClinicalTrials.gov study NCT05394194. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
ClinicalTrials.gov study NCT05548504. IPD Sharing: NO. Countries: 0. Publications: 0.
Hypofractionated Radiotherapy With 3.5 Gy Per Fraction for Early Glottic Cancer
ClinicalTrials.gov study NCT07197060. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Late-term Effects of Hypofractionated Chest Wall and Regional Nodal Irradiation in Patients With Breast Cancer
ClinicalTrials.gov study NCT04175821. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse
ClinicalTrials.gov study NCT04784221. IPD Sharing: NO. Countries: 0. Publications: 0.
Trial of Hypofractionated IMRT Boost Versus Conventional IMRT Boost for Localized High Risk Prostate Cancer
ClinicalTrials.gov study NCT04239599. IPD Sharing: NO. Countries: 0. Publications: 0.
Hypofractionated Whole Pelvic Radiotherapy of the Prostate
ClinicalTrials.gov study NCT02546427. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Combination of Hypofractionated Proton Therapy With Immunotherapy
ClinicalTrials.gov study NCT03764787. IPD Sharing: NO. Countries: 0. Publications: 0.
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
ClinicalTrials.gov study NCT02788058. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Postoperative Radiation of Patients With Breast Cancer in Extreme Hypofractionation.
ClinicalTrials.gov study NCT05452083. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
ClinicalTrials.gov study NCT06914050. IPD Sharing: NO. Countries: 0. Publications: 0.
Treatment of High-grade Gliomas Using Hypofractionated Radiation Therapy -a Phase I Clinical Trial
ClinicalTrials.gov study NCT03082846. IPD Sharing: NO. Countries: 0. Publications: 0.
scRNA-seq data from patients undergoing neoadjuvant BO-112 and hypofractionated radiation therapy in soft tissue carcoma
GEO Series GSE313859. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Spatial transcriptomic data from longitudinal tumor samples from one patient undergoing neoadjuvant BO-112 and hypofractionated radiation therapy in soft tissue carcoma
GEO Series GSE313858. Homo sapiens. 4 samples. Type: Other.
Dataset related to article "Impact of hypofractionated schemes in radiotherapy for locally advanced head and neck cancer patients."
<p>OBJECTIVE:</p> <p>To analyze two cohorts of locally advanced head and neck cancer (LAHNC) patients treated with two schedules of hypofractionated radiotherapy and 5 versus 3 mm clinical target volume-planning target volume (CTV-PTV) margins.</p> <p>METHODS:</p> <p>145 patients were included. The patient cohort was divided into two groups. Group A included 97 patients treated with 69.96/54.45 grays (Gy) to the high-risk and low-risk volumes, respectively, in 33 fractions, with 5 mm margins. Group B included 48 patients treated with 66/54 Gy in 30 fractions using 3 mm margins. Toxicity was recorded according to the Common Toxicity Criteria version 3. Patient outcomes for locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) were determined.</p> <p>RESULTS:</p> <p>Median follow-up was 26 months. In terms of toxicity, acute dysphagia worsened significantly (P = 0.003) in group B, whereas acute salivary toxicity tended to significance (P = 0.071). No significant late toxicity differences were recorded. Rates of LRC at 1 and 2 years were 90.1% ± 2.6% and 84.2% ± 3.4%, respectively, with superiority for group A (P = 0.045). The statistical significance remained for the low-dose level (P = 0.007) but not for high dose (P = 0.110). Rates of DFS at 1 and 2 years were 84.9% ± 3.1% and 76.5% ± 3.9%, respectively, whereas rates of OS were 95.9% ± 1.8% and 91.6% ± 2.7%, respectively. No differences were observed between the two groups in terms of DFS (P = 0.270) and OS (P = 0.152).</p> <p>CONCLUSION:</p> <p>The use of reduced CTV to PTV margins and dose reduction with hypofractionation schedule can improve the pattern of toxicity in LAHNC patients. This approach resulted in an increased rate of locoregional progression, particularly in low-risk regions.</p> <p>LEVEL OF EVIDENCE:</p> <p>4 Laryngoscope, 2019.</p>
Dataset related to article "Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis"s
<p>This record contains data related to article "Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis"</p> <p>Abstract</p> <p><strong>Introduction: </strong>The purpose of this study was to evaluate the impact of breast size on long-term toxicity and cosmesis in patients with breast cancer treated with hypofractionated simultaneous integrated boost (SIB) using volumetric modulated arc therapy (VMAT).</p> <p><strong>Patients and methods: </strong>Patients with early stage breast cancer were treated with 3-week hypofractionated SIB-VMAT to the whole breast (40.5 Gy) and tumor bed (48 Gy). Two cohorts were identified: small/medium- (< 1000 cm<sup>3</sup>) and large- (> 1000 cm<sup>3</sup>) breasted patients. Acute and late (at 2 and 5 years) skin toxicity and cosmetic data were analyzed. Univariate and multivariate analysis evaluated associations between toxicity and dosimetric/anatomical variables.</p> <p><strong>Results: </strong>From August 2010 to March 2017, a total of 1160 patients were treated; 831 had at least 2 years of follow-up and were analyzed. Treated skin area (TSA) receiving at least 20 Gy > 400 cm<sup>2</sup> and V<sub>105% of Boost</sub> > 5 cm<sup>3</sup> were significant predictors for acute skin toxicity. Multivariate analysis at 2 years was significant for boost volume > 70 cm<sup>3</sup>, TSA > 400 cm<sup>2</sup>, and breast size > 1500 cm<sup>3</sup>. At 5 year analysis (352 patients), none of the analyzed variables was significant. For cosmetic outcome, only the breast size (> 1000 cm<sup>3</sup>) and the boost size > 70 cm<sup>3</sup> at 2 and 5 years, respectively, confirmed significance.</p> <p><strong>Conclusions: </strong>The TSA > 400 cm<sup>2</sup> resulted as a significant predictor of both acute and late skin toxicity at 2 years; however, at 5 years, no breast size or dosimetric parameter suggested indications for increased toxicity. A worse cosmetic outcome was recorded at the 2-year follow up for large breasts, but was not confirmed at the 5-year follow-up. These long-term data suggest that hypofractionated SIB-VMAT is a viable modality also in large-breasted patients.</p>
Dataset related to article "Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy "
<p>This record contains raw data related to article “Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy"</p> <p>Abstract:</p> <p><strong>Background: </strong> This study evaluated the outcome, toxicity and predictive factors in patients unfit for concurrent chemo-radiotherapy (CT-RT) treated with hypofractionated sequential CT-RT or exclusive radiotherapy (RT) for locally advanced non-small cell lung cancer (LA-NSCLC).</p> <p><strong>Methods: </strong> We included patients affected by LA-NSCLC (stage IIA-IVA) treated with a total dose of 50-60 Gy in 20 fractions. The primary outcomes were local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS). Univariate analysis was used to correlate outcomes with prognostic factors.</p> <p><strong>Results: </strong> Between 2011 and 2019, 210 patients were treated, 113 (53.8%) with sequential CT-RT and 97 (46.2%) with exclusive RT. After a median follow-up of 15.3 months, 74 patients (35.2%) had a local progression and 133 (63.3%) had a distant progression. The one-, two- and five-year LC were 73.6%, 55.3% and 47.9%, respectively. At the time of analysis, 167 patients (79.5%) died. The one-, two- and five-year OS were 64.7%, 36% and 20%, respectively. PTV volume correlated with PFS (<em>p</em> = 0.001) and LC (<em>p</em> = 0.005). Acute and late toxicity occurred in 82% and 26% of patients.</p> <p><strong>Conclusions: </strong> Albeit with the known limitations of a retrospective and heterogeneous study, our work shows that hypofractionated sequential CT-RT or exclusive RT offer a good local control and toxicity profile and a promising survival rate in LA-NSCLC patients unfit for the concurrent CT-RT scheme.</p>
Dataset related to article "Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy A prospective evaluation of a case series and review of the literature"
<p>This record contains raw data related to article "Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy A prospective evaluation of a case series and review of the literature"</p> <p>To evaluate acute toxicity and cosmetic outcomes of hypofractionated simultaneous integrated boost (SIB) as adjuvant treatment after breast-conserving surgery and adjuvant chemotherapy and to review the association of chemotherapy and short fractionation with boost.</p> <p>MATERIALS AND METHODS:</p> <p>Patients presenting early-stage breast cancer were enrolled in a phase II trial. All patients received VMAT-SIB technique to the whole breast and tumor bed in 15 fractions, for a total dose of 40.5 and 48 Gy. Acute and late skin toxicities and breast pain were recorded. Cosmetic outcomes were also assessed as excellent/good or fair/poor.</p> <p>RESULTS:</p> <p>Between August 2010 and December 2015, 787 consecutive patients were treated and had at least 2 year follow-up. A subset of 175 patients underwent adjuvant chemotherapy (median age of 55 years) and was analysed. The median follow up was 39 months (range 24-80). At the end of RT treatment, skin toxicity was G1 in 51.1% of patients, G2 in 9.7%. At 2 years of follow up, it was G1 in 13.5% of patients, no cases ≥ G2; cosmetic outcome was excellent in 63.5% and good in 36.5% of the patients. No significant difference compared to the patients without systemic therapy was observed.</p> <p>CONCLUSION:</p> <p>Hypofractionated VMAT-SIB in patients who had undergone adjuvant systemic therapy was safe and well tolerated in terms of acute and early late settings and cosmesis. Our data confirmed the results of other studies published on the association of hypofractionation and chemotherapy or concomitant boost.</p> <p> </p> <p> </p> <p> </p> <p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.